Literature DB >> 3318449

Pharmacology of fenofibrate.

M J Chapman1.   

Abstract

This discussion outlines the major aspects of the human pharmacology of fenofibrate, a hypolipidemic agent. In view of its short half-life, efficient absorption, and elimination, fenofibrate would not appear to accumulate in either plasma or tissues. It is extensively absorbed only in the presence of food and is transported through the bloodstream by albumin. Fenofibrate is taken up by both the liver and kidney. Except for a small percentage (about 5 percent) reduced at the ketone moiety before conjugation, most drug is excreted as a conjugate in the urine. Less than 20 percent is excreted through the bile. In normal persons, at steady state with usual doses of 100 mg three times daily, the plasma half-life approximates 30 hours. Because fenofibrate is not dialyzable, it has a markedly prolonged half life in patients with renal failure and should not be used.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3318449     DOI: 10.1016/0002-9343(87)90867-9

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  15 in total

1.  A new in vitro lipid digestion - in vivo absorption model to evaluate the mechanisms of drug absorption from lipid-based formulations.

Authors:  Matthew F Crum; Natalie L Trevaskis; Hywel D Williams; Colin W Pouton; Christopher J H Porter
Journal:  Pharm Res       Date:  2015-12-24       Impact factor: 4.200

Review 2.  Fibrate therapy and renal function.

Authors:  Domenic A Sica
Journal:  Curr Atheroscler Rep       Date:  2009-09       Impact factor: 5.113

Review 3.  Lipid lowering drugs.

Authors:  P O'Connor; J Feely; J Shepherd
Journal:  BMJ       Date:  1990-03-10

Review 4.  Does combination therapy with statins and fibrates prevent cardiovascular disease in diabetic patients with atherogenic mixed dyslipidemia?

Authors:  Aris P Agouridis; Christos V Rizos; Moses S Elisaf; Theodosios D Filippatos
Journal:  Rev Diabet Stud       Date:  2013-08-10

5.  Over-the-counter fish oil use in a county hospital: Medication use evaluation and efficacy analysis.

Authors:  Amulya Tatachar; Margaret Pio; Denise Yeung; Elizabeth Moss; Diem Chow; Steven Boatright; Marissa Quinones; Annie Mathew; Jeffrey Hulstein; Beverley Adams-Huet; Zahid Ahmad
Journal:  J Clin Lipidol       Date:  2015-02-21       Impact factor: 4.766

Review 6.  Fenofibrate and metabolic syndrome.

Authors:  Aldi T Kraja; Michael A Province; Robert J Straka; Jose M Ordovas; Ingrid B Borecki; Donna K Arnett
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2010-06       Impact factor: 2.895

7.  Distribution of fenofibric acid in lipoprotein fractions of patients.

Authors:  M Nobilis; J Kvetina; P Anzenbacher; T Vontor; D Svoboda; M Brátová; D Solichová; Z Zadák; V Bláha; J Vlcek
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Apr-Jun       Impact factor: 2.441

8.  Retrospective comparison of the effectiveness of a fenofibrate 145 mg formulation compared with the standard 160 mg tablet.

Authors:  Michael H Davidson; Peter H Jones
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

9.  Assessment of Age-Related Changes in Pediatric Gastrointestinal Solubility.

Authors:  Anil R Maharaj; Andrea N Edginton; Nikoletta Fotaki
Journal:  Pharm Res       Date:  2015-07-29       Impact factor: 4.200

Review 10.  The role of fibrates in managing hyperlipidemia: mechanisms of action and clinical efficacy.

Authors:  Sergio Fazio; MacRae F Linton
Journal:  Curr Atheroscler Rep       Date:  2004-03       Impact factor: 5.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.